Mandate

Vinge has advised Titania Holding AB (publ) in connection with its listing on Nasdaq First North Growth Market

Vinge has advised Titania Holding AB (publ) (“Titania”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 29 November 2021 and the first day of trading was 10 December 2021.

The price in the offering was SEK 20 per class B share, corresponding to a market capitalization of all of Titania’s shares upon completion of the offering of approximately SEK 1.4 billion.

Titania is a fast-growing real estate company focusing on the Stockholm region. Its operations consist of project development, production and management. Titania participates throughout the entire value chain, from early stages of city and project development to land acquisitions, production and rental and eventually also long-term property management. Titania possesses expertise throughout all steps of the value chain and has capacity to carry out large projects within urban development, adding value in terms of increased social and financial sustainability.

Vinge’s team primarily consisted of David Andersson, Amanda Knutsson, Anna Grigorian and Anna Svensson (Capital Markets and Public M&A), Frida Ställborn (Real Estate), Kamyar Najmi and Benjamin Vafaeian (Banking and Finance).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024